Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Targeting the Oncogenic Drivers of Rhabdomyosarcoma

Friday, April 24, 2015
Bethesda, MD

Anticipated goals: Agreement and Update on:  1.) Collaboration to validate prognostic markers in rhabdomyosarcoma.  2.)  Plan for genomic investigation for every sample entered on national/international trials.  3.) Collaboration for data unification and sharing of samples. 4. Plan for clinical trials of targeted agents in rhabdomyosarcoma.

Dr. Javed Khan, (301) 480-0314,

Co-funding Institute(s):
National Cancer Institute
Office of Rare Diseases Research

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.